Global Diabetes Drugs Market to 2023 – A Diversifying Treatment Landscape as GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following Landmark Cardiac Outcomes – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Global
Diabetes Drugs Market to 2023 – A Diversifying Treatment Landscape as
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Gain Ground Following
Landmark Cardiac Outcomes”
report has been added to Research
and Markets’
offering.

Global Diabetes Drugs Market to 2023 comprehensively reviews
the strategies of key players in the DM market, and provides market
share forecasts. Pipeline and marketed products are analyzed in detail,
along with the impact that products expected to come to market between
2016 and 2023 will have on existing established products. Licensing and
co-marketing deals in DM are analyzed by region and value.

The DM market has undergone a dynamic shift over the past decade,
primarily due to the entry of three new non-insulin drug classes for
T2DM: glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl
peptidase 4 (DPP-4) inhibitors and sodium-glucose linked transporter 2
(SGLT-2) inhibitors. Increased market diversification is expected to
continue throughout the forecast period due to patent expiries for major
insulin products and increased uptake of non-insulin drugs.

Incidence of diabetes mellitus (DM), and most notably type 2 diabetes
mellitus (T2DM), which accounts for more than 90% of all DM cases, is
growing rapidly on a global scale. The US is expected to experience the
greatest rise in T2DM prevalence, and incidence rates are also expected
to increase to about 4% by 2023. Several factors are driving the
increase of T2DM, with aging population and the prevalence of highly
calorific diets being some of the key drivers.

In 2016, the top five products, all of which are insulin products,
commanded almost half of the market by sales. By 2023, the top 10
products are expected to occupy more than 40% of the market share, many
of which will be non-insulin products.

Competition will intensify over the forecast period as more companies
enter the DM market space. However, Novo Nordisk, which is currently the
leading player in terms of market share, is expected to maintain its
position throughout the forecast period. Despite declining revenues for
high-grossing products such as Levemir (insulin detemir), more recent
market additions such as Tresiba (insulin degludec), as well as the
upcoming pipeline products such as semaglutide and oral semaglutide are
expected to more than compensate.

Key Topics Covered:

1. List of Tables & Figures

2 Introduction

3 Key Marketed Products

4 Pipeline Landscape Assessment

5 Multi-scenario Market Forecast to 2023

6 Company Analysis and Positioning

7 Strategic Consolidations

8 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/d8hv6n/global_diabetes

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Endocrine
and Metabolic Disorders Drugs